Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03685747
Other study ID # 12451
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 15, 2018
Est. completion date October 1, 2020

Study information

Verified date March 2022
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vancomycin is the most commonly used empiric treatment for infectious peritonitis in patients on peritoneal dialysis. Current dosing and monitoring for safety and efficacy is empiric, especially for those on rapid-cycling modalities. The goal of this study is to understand the pharmacokinetics of vancomycin in patients on rapid-cycling peritoneal dialysis modalities in order to derive an optimal dosing regimen.


Description:

Peritoneal dialysis (PD) is a form of renal replacement therapy indicated for those with acute kidney injury or end stage renal disease. Currently, two modalities of PD exist and is individualized based on patient and life-style specific factors. Continuous ambulatory peritoneal dialysis (CAPD) allows 4 - 5 exchanges performed manually whereas automated peritoneal dialysis (APD) involves continuous, automated, cyclical exchanges performed by a device at home during the night. Peritonitis is a common complication in PD and accounts for a large portion of hospital readmission and mortality. Vancomycin is the most common antibiotic recommended and has notable gram-positive coverage used empirically during suspected peritonitis. Despite widespread use, vancomycin lacks good pharmacokinetic characterization in PD. Early pharmacokinetic studies using vancomycin were conducted predominantly in patients on CAPD on glucose-based prescriptions. Data is non-existent in PD patients administered the novel dialysate solution icodextrin, or those treated with overnight APD. The impact of residual kidney function (RKF) on vancomycin in PD is also lacking. Enhanced vancomycin clearance in RKF may result in under-dosing, while overdosing may result in nephrotoxicity and loss of clinically important RKF. The investigators will characterize the pharmacokinetic profile of vancomycin following a single intraperitoneal dose of vancomycin in icodextrin dialysate to non-infected PD patients and examine the relationship between RKF and vancomycin clearance using serum, dialysate and urine. The goal is to use this data in non-infected subjects to generate information to guide vancomycin dosing in patients on rapid-cycling PD modalities.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date October 1, 2020
Est. primary completion date August 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Adult male or females between 18 - 85 years old - Stabilized on a PD regimen for > 3 months prior to study initiation Exclusion Criteria: - Clinically significant disease unrelated to renal impairment or deemed unfit by the investigator - Allergy or hypersensitivity to vancomycin or icodextrin-containing dialysis solution - Active peritonitis infection - Previous intraperitoneal antibiotic treatment within 2 months - Previous intravenous vancomycin treatment within 2 months - Hemoglobin < 9 g/dL - Pregnant or breast-feeding women

Study Design


Related Conditions & MeSH terms

  • Peritoneal Dialysis-associated Peritonitis
  • Peritonitis

Intervention

Drug:
Vancomycin
Vancomycin one-time 20 mg/kg intraperitoneal dose.

Locations

Country Name City State
United States Thomas Jefferson University Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lam E, Ting Kayla Lien Y, Kraft WK, Stickle DF, Piraino B, Zhang J. Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis. Clin Transl Sci. 2021 Nov 9. doi: 10.1111/cts.13182. [Epub ahead of print] — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Total Plasma Concentration (Cmax) Total systemic plasma concentration following 12-hour dwell Day: 1
Primary Time to Maximum Plasma Concentration (Tmax) Time (hours) to achieve the maximum plasma concentration Day: 1
Primary Area Under the Concentration-time Curve (AUC0-inf) AUC based on vancomycin plasma concentrations Days: 1-7
Primary Total Body Clearance (CLtotal) Total vancomycin plasma vancomycin clearance Days: 1-7
Primary Dialytic Clearance Vancomycin clearance from peritoneal dialysis Days: 1-7
Secondary Adverse Events Any adverse events throughout entirety of study as assessed by physician-investigator Days: 1-7
See also
  Status Clinical Trial Phase
Completed NCT03264625 - The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis Phase 2
Suspended NCT05300191 - In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device
Recruiting NCT03046511 - Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter. Phase 3
Recruiting NCT05285436 - A Prospective Clinical Study to Assess the Clinical Utility of Turbidity in Patients Using In-Home Peritoneal Dialysis N/A
Recruiting NCT05971537 - Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis Phase 4
Recruiting NCT05860270 - Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis Phase 4
Completed NCT01293799 - Prevention of Peritonitis in Peritoneal Dialysis N/A
Withdrawn NCT03675854 - Defining the Optimal Duration of Treatment for "Low-Risk" Peritoneal Dialysis-Related Peritonitis Phase 4
Completed NCT05450523 - Neutrophil Gelatinase-Associated Lipocalin (NGAL) Rapid Test (Colloidal Gold) Clinical Trial Protocol
Terminated NCT00801775 - Improved Diagnosis of Peritoneal Dialysis Peritonitis by Calorimetry N/A
Completed NCT04515498 - A Prospective Clinical Study of the CloudCath System During In-home Peritoneal Dialysis